MARKET

ALEC

ALEC

Alector
NASDAQ
1.220
+0.010
+0.83%
After Hours: 1.240 +0.02 +1.64% 19:36 12/05 EST
OPEN
1.210
PREV CLOSE
1.210
HIGH
1.260
LOW
1.190
VOLUME
1.36M
TURNOVER
--
52 WEEK HIGH
3.400
52 WEEK LOW
0.8700
MARKET CAP
133.16M
P/E (TTM)
-1.1399
1D
5D
1M
3M
1Y
5Y
1D
Alector to Participate in Bank of America CNS Therapeutics Conference
Reuters · 5d ago
Weekly Report: what happened at ALEC last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at ALEC last week (1117-1121)?
Weekly Report · 11/24 09:16
Mizuho Securities downgrades Alector (ALEC) to a Hold
TipRanks · 11/20 06:25
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
NASDAQ · 11/18 15:33
Alector price target lowered to 75c from $1.50 at Morgan Stanley
TipRanks · 11/17 12:41
Alector’s Strategic and Financial Challenges Prompt Sell Rating Amid Clinical Setbacks
TipRanks · 11/17 11:45
ALECTOR INC <ALEC.O>: MORGAN STANLEY CUTS TARGET PRICE TO $0.75 FROM $1.50
Reuters · 11/17 11:32
More
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Webull offers Alector Inc stock information, including NASDAQ: ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.